ANI Pharmaceuticals, Inc. (ANIP)
USD 72.95
(3.2%)
USD 72.95
(3.2%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 471.67 Million USD | 11.89% |
| 2022 | 421.54 Million USD | 2.1% |
| 2021 | 412.85 Million USD | 55.51% |
| 2020 | 265.49 Million USD | 8.81% |
| 2019 | 243.99 Million USD | 4.57% |
| 2018 | 233.34 Million USD | -1.7% |
| 2017 | 237.38 Million USD | 54.93% |
| 2016 | 153.21 Million USD | 22.39% |
| 2015 | 125.18 Million USD | 1.02% |
| 2014 | 123.92 Million USD | 3402.66% |
| 2013 | 3.53 Million USD | -66.6% |
| 2012 | 10.59 Million USD | -56.87% |
| 2011 | 24.56 Million USD | -4.12% |
| 2010 | 25.61 Million USD | 24.33% |
| 2009 | 20.6 Million USD | 434.82% |
| 2008 | 3.85 Million USD | 154.18% |
| 2007 | 1.51 Million USD | -64.74% |
| 2006 | 4.29 Million USD | 56.03% |
| 2005 | 2.75 Million USD | 44.52% |
| 2004 | 1.9 Million USD | 116.38% |
| 2003 | 881.2 Thousand USD | -29.85% |
| 2002 | 1.25 Million USD | 35.4% |
| 2001 | 927.76 Thousand USD | -1.43% |
| 2000 | 941.26 Thousand USD | 186.0% |
| 1999 | 329.11 Thousand USD | -59.76% |
| 1998 | 817.91 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 464.99 Million USD | 0.53% |
| 2024 Q1 | 462.56 Million USD | -1.93% |
| 2023 Q4 | 471.67 Million USD | 8.38% |
| 2023 Q3 | 435.2 Million USD | 2.43% |
| 2023 FY | 471.67 Million USD | 11.89% |
| 2023 Q1 | 425.74 Million USD | 1.0% |
| 2023 Q2 | 424.86 Million USD | -0.21% |
| 2022 Q3 | 402.43 Million USD | -2.88% |
| 2022 FY | 421.54 Million USD | 2.1% |
| 2022 Q1 | 398.75 Million USD | -3.42% |
| 2022 Q2 | 414.37 Million USD | 3.92% |
| 2022 Q4 | 421.54 Million USD | 4.75% |
| 2021 Q4 | 412.85 Million USD | 47.95% |
| 2021 FY | 412.85 Million USD | 55.51% |
| 2021 Q3 | 279.05 Million USD | -3.19% |
| 2021 Q2 | 288.24 Million USD | 10.81% |
| 2021 Q1 | 260.13 Million USD | -2.02% |
| 2020 Q2 | 274.04 Million USD | -2.5% |
| 2020 Q4 | 265.49 Million USD | -0.74% |
| 2020 Q3 | 267.48 Million USD | -2.4% |
| 2020 FY | 265.49 Million USD | 8.81% |
| 2020 Q1 | 281.06 Million USD | 15.19% |
| 2019 Q4 | 243.99 Million USD | 0.14% |
| 2019 FY | 243.99 Million USD | 4.57% |
| 2019 Q2 | 239.25 Million USD | 1.95% |
| 2019 Q1 | 234.67 Million USD | 0.57% |
| 2019 Q3 | 243.64 Million USD | 1.84% |
| 2018 Q2 | 239.06 Million USD | 0.29% |
| 2018 FY | 233.34 Million USD | -1.7% |
| 2018 Q4 | 233.34 Million USD | -5.52% |
| 2018 Q3 | 246.97 Million USD | 3.31% |
| 2018 Q1 | 238.37 Million USD | 0.42% |
| 2017 FY | 237.38 Million USD | 54.93% |
| 2017 Q4 | 237.38 Million USD | 26.49% |
| 2017 Q3 | 187.66 Million USD | 2.73% |
| 2017 Q2 | 182.67 Million USD | -1.22% |
| 2017 Q1 | 184.92 Million USD | 20.7% |
| 2016 Q4 | 153.21 Million USD | 1.77% |
| 2016 Q2 | 144.22 Million USD | 9.75% |
| 2016 FY | 153.21 Million USD | 22.39% |
| 2016 Q1 | 131.41 Million USD | 4.97% |
| 2016 Q3 | 150.54 Million USD | 4.39% |
| 2015 FY | 125.18 Million USD | 1.02% |
| 2015 Q1 | 121.24 Million USD | -2.16% |
| 2015 Q4 | 125.18 Million USD | -1.73% |
| 2015 Q3 | 127.38 Million USD | 5.61% |
| 2015 Q2 | 120.62 Million USD | -0.51% |
| 2014 Q2 | 3.82 Million USD | -16.05% |
| 2014 Q4 | 123.92 Million USD | 1421.47% |
| 2014 Q3 | 8.14 Million USD | 112.77% |
| 2014 Q1 | 4.56 Million USD | 28.89% |
| 2014 FY | 123.92 Million USD | 3402.66% |
| 2013 Q3 | 6.59 Million USD | 7.04% |
| 2013 Q1 | 9.32 Million USD | -11.97% |
| 2013 Q4 | 3.53 Million USD | -46.37% |
| 2013 FY | 3.53 Million USD | -66.6% |
| 2013 Q2 | 6.16 Million USD | -33.91% |
| 2012 Q4 | 10.59 Million USD | -3.01% |
| 2012 Q1 | 16.57 Million USD | -32.51% |
| 2012 FY | 10.59 Million USD | -56.87% |
| 2012 Q2 | 16.37 Million USD | -1.24% |
| 2012 Q3 | 10.92 Million USD | -33.29% |
| 2011 FY | 24.56 Million USD | -4.12% |
| 2011 Q4 | 24.56 Million USD | -20.09% |
| 2011 Q3 | 30.74 Million USD | -1.57% |
| 2011 Q2 | 31.23 Million USD | 1.84% |
| 2011 Q1 | 30.66 Million USD | 19.71% |
| 2010 Q3 | 25.45 Million USD | 1.2% |
| 2010 Q1 | 24.31 Million USD | 17.97% |
| 2010 FY | 25.61 Million USD | 24.33% |
| 2010 Q2 | 25.15 Million USD | 3.48% |
| 2010 Q4 | 25.61 Million USD | 0.63% |
| 2009 FY | 20.6 Million USD | 434.82% |
| 2009 Q1 | 3.1 Million USD | -19.42% |
| 2009 Q2 | 3.71 Million USD | 19.71% |
| 2009 Q3 | 4.77 Million USD | 28.54% |
| 2009 Q4 | 20.6 Million USD | 331.35% |
| 2008 Q4 | 3.85 Million USD | -15.7% |
| 2008 Q3 | 4.57 Million USD | 26.2% |
| 2008 Q2 | 3.62 Million USD | 23.73% |
| 2008 FY | 3.85 Million USD | 154.18% |
| 2008 Q1 | 2.92 Million USD | 93.08% |
| 2007 Q2 | 2.61 Million USD | 7.4% |
| 2007 Q4 | 1.51 Million USD | -32.17% |
| 2007 FY | 1.51 Million USD | -64.74% |
| 2007 Q1 | 2.43 Million USD | -43.47% |
| 2007 Q3 | 2.23 Million USD | -14.39% |
| 2006 FY | 4.29 Million USD | 56.03% |
| 2006 Q4 | 4.29 Million USD | 152.03% |
| 2006 Q3 | 1.7 Million USD | -26.63% |
| 2006 Q2 | 2.32 Million USD | -16.67% |
| 2006 Q1 | 2.79 Million USD | 1.26% |
| 2005 Q4 | 2.75 Million USD | 71.47% |
| 2005 Q1 | 1.81 Million USD | -5.04% |
| 2005 Q2 | 1.55 Million USD | -14.36% |
| 2005 FY | 2.75 Million USD | 44.52% |
| 2005 Q3 | 1.6 Million USD | 3.64% |
| 2004 FY | 1.9 Million USD | 116.38% |
| 2004 Q4 | 1.9 Million USD | 42.72% |
| 2004 Q1 | 1.14 Million USD | 30.11% |
| 2004 Q3 | 1.33 Million USD | 13.61% |
| 2004 Q2 | 1.17 Million USD | 2.56% |
| 2003 Q1 | 554.87 Thousand USD | -55.83% |
| 2003 FY | 881.2 Thousand USD | -29.85% |
| 2003 Q3 | 700.12 Thousand USD | -2.85% |
| 2003 Q4 | 881.2 Thousand USD | 25.86% |
| 2003 Q2 | 720.63 Thousand USD | 29.87% |
| 2002 Q3 | 692.81 Thousand USD | -5.83% |
| 2002 Q2 | 735.69 Thousand USD | 8.47% |
| 2002 FY | 1.25 Million USD | 35.4% |
| 2002 Q1 | 678.24 Thousand USD | -26.89% |
| 2002 Q4 | 1.25 Million USD | 81.32% |
| 2001 Q2 | 940.72 Thousand USD | 18.4% |
| 2001 Q3 | 1.02 Million USD | 9.36% |
| 2001 Q4 | 927.76 Thousand USD | -9.82% |
| 2001 FY | 927.76 Thousand USD | -1.43% |
| 2001 Q1 | 794.52 Thousand USD | -15.59% |
| 2000 Q3 | 697.32 Thousand USD | 182.07% |
| 2000 FY | 941.26 Thousand USD | 186.0% |
| 2000 Q1 | 286.29 Thousand USD | 0.0% |
| 2000 Q2 | 247.21 Thousand USD | -13.65% |
| 2000 Q4 | 941.26 Thousand USD | 34.98% |
| 1999 FY | 329.11 Thousand USD | -59.76% |
| 1998 FY | 817.91 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 660.79 Million USD | 28.62% |
| Theratechnologies Inc. | 98.63 Million USD | -378.181% |
| Safety Shot Inc | 3.89 Million USD | -12018.902% |
| Cosmos Health Inc. | 30.25 Million USD | -1459.119% |
| Cronos Group Inc. | 43.73 Million USD | -978.453% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 42.294% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -873.626% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -160.073% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -3329.269% |
| ProPhase Labs, Inc. | 42.54 Million USD | -1008.671% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -5286.855% |
| Dynavax Technologies Corporation | 375.02 Million USD | -25.771% |
| Radius Health, Inc. | 804.29 Million USD | 41.355% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -5028.77% |
| Alvotech | 1.88 Billion USD | 74.945% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -7582.471% |
| Alpha Teknova, Inc. | 38.55 Million USD | -1123.504% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -244.611% |
| SCYNEXIS, Inc. | 55.45 Million USD | -750.628% |
| Harrow Health, Inc. | 241.75 Million USD | -95.105% |
| Biofrontera Inc. | 23.13 Million USD | -1938.433% |
| DURECT Corporation | 30.4 Million USD | -1451.25% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 3.239% |
| OptiNose, Inc. | 194.33 Million USD | -142.711% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -2148.404% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -187.772% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -798.148% |
| SIGA Technologies, Inc. | 57.97 Million USD | -713.548% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -114.592% |
| Shineco, Inc. | 47.6 Million USD | -890.875% |
| Phibro Animal Health Corporation | 725.54 Million USD | 34.99% |
| Procaps Group S.A. | 462.06 Million USD | -2.079% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -3263.807% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -214773.447% |
| Viatris Inc. | 27.21 Billion USD | 98.267% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -7582.471% |
| Rockwell Medical, Inc. | 30.88 Million USD | -1427.34% |
| Incannex Healthcare Limited | 5.83 Million USD | -7990.446% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -421.883% |
| Tilray Brands, Inc. | 892.11 Million USD | 47.129% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 50.239% |
| PetIQ, Inc. | 645.22 Million USD | 26.898% |
| Silver Spike Investment Corp. | 3 Million USD | -15571.079% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 53.73% |
| Journey Medical Corporation | 56.49 Million USD | -734.834% |
| Alimera Sciences, Inc. | 107.35 Million USD | -339.362% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -2112.789% |
| Assertio Holdings, Inc. | 148.41 Million USD | -217.805% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -24777.727% |
| Embecta Corp. | 2.03 Billion USD | 76.834% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -5455.283% |
| Procaps Group, S.A. | 462.06 Million USD | -2.079% |
| PainReform Ltd. | 2.69 Million USD | -17427.796% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -172.035% |
| Hempacco Co., Inc. | 18.82 Million USD | -2405.913% |
| Talphera, Inc. | 6.29 Million USD | -7398.776% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 33.025% |
| Alvotech | 1.88 Billion USD | 74.945% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 43.53% |
| Kamada Ltd. | 109.96 Million USD | -328.917% |
| Indivior PLC | 1.95 Billion USD | 75.827% |
| Currenc Group, Inc. | 177.67 Million USD | -165.468% |
| Evoke Pharma, Inc. | 9.64 Million USD | -4788.774% |
| Flora Growth Corp. | 17.22 Million USD | -2638.782% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -5455.283% |
| Evolus, Inc. | 209.68 Million USD | -124.941% |
| HUTCHMED (China) Limited | 536.38 Million USD | 12.065% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 46.001% |
| Akanda Corp. | 12.66 Million USD | -3623.082% |